The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced by a large upswing in the number of investigational new drug (IND) applications. Based on this activity, we anticipate that the number of product approvals for cell and gene therapies will grow in the coming years, reflecting significant scientific advancement and the clinical promise of these new innovations.
{iframe}https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629493.htm{/iframe}